The United Arab Emirates has transformed the medical structure of the region as it slowly moves towards attaining leadership in medical treatments and complex procedures. It has stepped up on the list with a pioneering treatment led by Abu Dhabi.
The capital has witnessed a revolutionary process that focuses on the safety and efficacy of using the CAR T-Cell treatment module especially for hematologic or blood cancers such as lymphoma, myeloma, and certain types of leukemia. This is an exemplary step in the context of the region as it is the first of its kind treatment here.
On Saturday, the Emirati nation began its experiment to locally manufacture CAR T-Cell treatment at Abu Dhabi Stem Cells Center. The T-Cells will be locally reprogrammed and tested for their effectiveness so that they get better results when it comes to treating cancer.
The unit for the stem cell treatment ADSCC was founded in 2019 and since then it has grown threefold when it comes to experimenting with new and life-changing technologies. The prime objective with which this unit was set up was to conduct radical research and make strong yet effective transformations in the country by providing them with the best medical treatments.
Though the west has already seen CAR T-Cell therapy, it has not yet gained an easy, effective way of transmission and at a time like this, it has found an experimental ground in the UAE. The treatment represents a new form of immunotherapy that essentially targets the defense system maintained by the body by reprogramming T-Cells.
T-Cell is an extremely important component of the body when it comes to determining anti-tumor response. Now instead of an external drug, these reprogrammed cells themselves become a living drug that helps in mobilizing through the body by constantly targeting the immune system to attack the disease.
The importance of this clinical trial cannot be stressed enough and this was further emphasized by Dr. Fatema Al Kaabi, Director of the Abu Dhabi Bone Marrow Transplant Program and Co-Principal Investigator of the CAR T-Cell clinical trial, who said that the team is proud to have become the first in the region to locally manufacture this innovative treatment.
This is a step towards making UAE becoming a leader in the knowledge-based economy and this further became evident with the amount of effort that the leadership has put in executing these clinical trials.
As for the treatment, the CAR T-Cell will involve the use of apheresis, which is a minimally invasive blood donation process that differentiates the components of the bloss for analysis and treatment. To this, a genetic modification is performed to the T-Cell and it will attack only tumor cells.
Comments
Post a Comment